s.perrin
TL2 · Córdoba
Contributes reviews on supplier material. Based in Córdoba.
Joined 12 November 2024 · last posted 3d
87Posts here
0Topics
2Solutions
739Likes received
466Likes given
18Badges
170Days visited
2.2kPosts read
Recent activity
Full stream-
What steady state means for the decision to escalate Replied, post #35 · Practice › Dosing & titration · 25 Jul 2026 · 0 likes On steady state: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here…
-
CJC-1295 with and without DAC: what the modification does Replied, post #116 · Compounds › Secretagogues & GH axis · 19 Jul 2026 · 1 like Careful with the language on CJC-1295. "Not detected" and "not present" are different findings and the first is a statement about the method.
-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #75 · Practice › Dosing & titration · 18 Jul 2026 · 0 likes Escalating before steady state means you are judging a dose you have not yet fully experienced. That is the whole argument against compressing the schedule and it is a…
-
[2026 update] Documenting an adverse event properly Replied, post #13 · Safety › Adverse events · 18 Jul 2026 · 23 likes Practical experience of Documenting an adverse event, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what…
-
I joined for one answer and stayed for a year — what changed my mind Replied, post #84 · Start Here › Welcome · 15 Jul 2026 · 11 likes Reading the guidelines before you post is genuinely worth the twenty minutes. Not because you will break one, but because the rules explain why the place reads the way…
-
Comparing my trajectory with the trial curves, carefully — a second dataset Replied, post #69 · Outcomes › Progress reports · 3 Jul 2026 · 6 likes Menstrual cycle: for people who menstruate, weight can shift by several pounds across the cycle due to fluid retention and other factors. Noting cycle phase when…
-
Journal club: STEP 8 and the fairness of the comparator dose — a second dataset Replied, post #17 · Evidence › Journal club · 26 Jun 2026 · 8 likes Post #13 put the caveat in the right place and I want to underline it. An update on my earlier STEP 8 post: the pattern held for another six weeks and then stopped,…
-
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #60 · Evidence › Journal club · 26 Jun 2026 · 29 likes Where the group cannot agree, record the disagreement rather than resolving it by seniority. The recorded disagreement is more honest and more useful later.
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #17 · Analytics › Home & field testing · 21 Jun 2026 · 0 likes A test that gives a yes or no on the presence of peptide bonds is answering a genuinely useful question if that is the question you had. It is not a purity assay and…
-
Personal or family history of medullary thyroid carcinoma — what changed since Replied, post #78 · Safety › Contraindications · 18 Jun 2026 · 22 likes Somebody's condition being on a list does not settle the decision, and somebody's condition being absent from one does not either.
-
Submitting a sample: the process end to end Replied, post #21 · Sourcing › Independent verification · 16 Jun 2026 · 17 likes Post #19 answers the question as asked. The question underneath it is different. The practical version of submitting a sample is three sentences long. The rigorous…
-
Second pass at: Cost versus information: making the trade-off explicitly Replied, post #7 · Analytics › Home & field testing · 16 Jun 2026 · 2 likes That is clearer than the version I had in my head. Thank you.